Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Twist Bioscience Corp — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.89 (market cap $3.56B), while Twist Bioscience Corp trades at $161.76 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.8× GraniteShares 2x Long NVDA Daily ETF's market cap, and GraniteShares 2x Long NVDA Daily ETF is more actively traded (9,740,643 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Twist Bioscience Corp for 27 Days on average.
| NVDL | TWST | |
|---|---|---|
Market Cap | $3.56B | $10.08B |
Volume | 9,740,643 | 4,229,037 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $205.00 |
52-Week Low | $21.76 | $25.45 |
Typical Hold Time | 15 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.
While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
